Associate Director, HEOR & RWE

Select how often (in days) to receive an alert:

Type of

Contract:

Full-time Employment / Unlimited

Job Requisition

About Servier

Servier in the U.S. is a Boston-based, commercial-stage biopharmaceutical company launched by Servier Group in 2018. As a privately held organization, Servier is uniquely positioned to advance cutting-edge science, tackle underserved therapeutic areas and make patients the focus of every strategic decision.

Role Summary

The Associate Director, HEOR/RWE, Tovorafenib, is a key member of the HEOR and Scientific Communication team within the US Medical Affairs organization. This individual will be responsible for the strategic development and execution of evidence generation initiatives for Tovorafenib, specifically designed to address medical, access, and other identified value gaps. A key focus will be leading evidence strategies to drive leadership in the Relapsed/Refractory (R/R) setting while spearheading the health economics, real-world evidence, and patient-reported outcomes strategies to support the upcoming First-Line (1L) launch.

This individual will partner closely with US Medical Affairs, Market Access, Commercial, Clinical Development, and Translational Science, as well as Global cross‑functional and alliance partners (e.g., Ipsen), to ensure the value of Tovorafenib is fully demonstrated and communicated through robust evidence initiatives that resonate with patients, providers, and payers.

Primary Responsibilities

Key Responsibilities:
Associate Director

• Strategic Leadership & Planning:
  • Co-create and lead the comprehensive evidence strategy (e.g., economic, comparative effectiveness) and operational plans for Tovorafenib, focusing on life-cycle management in R/R and preparing the value proposition for the 1L market entry.
  • Provide scientific support to facilitate market access and payer negotiations for pipeline and on-market assets.
  • Collaborate with clinical development teams to design and incorporate appropriate patient-reported outcomes (PRO) measures within clinical trials, serving as a Subject Matter Expert (SME) for engagements with regulatory and payer bodies.
  • Maintain an up-to-date awareness of the industry’s regulatory, payer, and policy landscape and its potential impact on evidence generation.
  • Mentor junior team members and contribute to a culture of learning, integrity, and innovation within the Value, Evidence and Communication function.
• Evidence Generation and Impact Measurement:
  • Oversee the end-to-end delivery of RWE studies (e.g., database analysis, chart reviews, prospective registries) to characterize unmet needs and practice patterns in 1L and R/R settings to continue driving leadership.
  • Deliver U.S. economic models and AMCP dossiers to optimize patient access and reimbursement ahead of the 1L Tovorafenib launch.
  • Ensure all research initiatives strictly adhere to internal study governance processes for evidence generation projects, ensuring high ethical and scientific standards. This includes obtaining necessary internal approvals and ensuring cross-functional alignment throughout study execution.
  • Work with external vendors and internal teams to design and execute oncology evidence projects, ensuring ethical and scientific standards are appropriately met.
  • Track and communicate project progress, manage budgets, and oversee external vendors/CROs to ensure timely and quality delivery.
  • Ensure timely measurement and communication of the external and internal impact of evidence.
  • In collaboration with the Evidence Communication team, translate research outputs into practical tools and resources (e.g., value decks, proactive or reactive field materials) that equip field medical and access teams to communicate Tovorafenib's value effectively to healthcare decision‑makers.
• Alliance Management & Global
  
  Collaboration:
  
  
  • Serve as a key Evidence Generation point of contact for the Ipsen alliance, ensuring strategic alignment on evidence generation activities for Tovorafenib.
  • Coordinate with Servier Global counterparts to ensure US evidence generation strategies complement and support global value narratives.
  • Manage the collaborative review of…